Gland Pharma receives SEBI nod to launch IPO
According to investment banking sources, the IPO would be worth over Rs 5,000 crore.
New Delhi: Gland Pharma has received capital markets regulator Sebi''s go-ahead to launch an initial public offer that includes fresh issue of shares worth up to Rs 1,250 crore.
Apart from the fresh issue, there is an offer for sale (OFS) of a little over 3.4 crore shares as part of the initial public offering.
The Hyderabad-based company, backed by China''s Fosun Pharma, develops, manufactures and markets complex injectables.
The company filed draft papers in July and obtained Sebi''s observation on October 19 to float an IPO, an update with the capital markets showed on Monday.
Sebi''s observation is necessary for any company to launch public issues like initial public offer (IPO), follow-on public offer (FPO) and rights issue.
Going by the draft papers, the IPO comprises fresh shares worth up to Rs 1,250 crore and OFS of up to 3,48,63,635 shares. The latter includes sale of up to 1,93,68,686 shares by Fosun Pharma Industrial Pte Ltd, 1,00,47,435 shares by Gland Celsus Bio Chemicals Pvt Ltd, 35,73,014 shares by Empower Discretionary Trust and 18,74,500 shares by Nilay Discretionary Trust.
According to investment banking sources, the IPO would be worth over Rs 5,000 crore.
This could probably be the first big Indian company with a Chinese parent to go for public listing.
The company''s promoters are Fosun Singapore and Shanghai Fosun Pharma.
The proceeds from the fresh issue of shares will be utilised for working capital, capital expenditure and general corporate purposes, as per the draft papers.
Gland Pharma was founded by P V N Raju in 1978 and Fosun Pharma acquired 74 per cent stake in the company in 2017.
Shares of the company are proposed to be listed on the BSE and the NSE.
Kotak Mahindra Capital Company Ltd, Citigroup Global Markets India Pvt Ltd, Haitong Securities India Pvt Ltd and Nomura Financial Advisory and Securities (India) Pvt Ltd are the book running lead managers to the IPO.
The company sells its products primarily under a business-to-business model in over 60 countries, including the US, Canada, Australia and India. It had 3,791 people across its facilities in India as on March 31, 2020.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.